Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
During the past 12 months, Sartorius Stedim Biotech's average EPS without NRIGrowth Rate was 30.70% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was -30.40% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was -15.40% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 8.70% per year.
During the past 13 years, Sartorius Stedim Biotech's highest 3-Year average EPS without NRI Growth Rate was 82.90% per year. The lowest was -30.40% per year. And the median was 24.80% per year.
Sartorius Stedim Biotech (CHIX:DIMp) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Sartorius Stedim Biotech Earnings per Share (Diluted) Related Terms
Sartorius Stedim Biotech Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Sartorius Stedim Biotech's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sartorius Stedim Biotech Earnings per Share (Diluted) Chart
CHIX:DIMP vs ISRG, BDX, MDLN: Earnings per Share (Diluted) Comparison
For the Medical Instruments & Supplies subindustry, Sartorius Stedim Biotech's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sartorius Stedim Biotech PE Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sartorius Stedim Biotech's PE Ratio distribution charts can be found below:
* The bar in red indicates where Sartorius Stedim Biotech's PE Ratio falls into.
Sartorius Stedim Biotech Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Sartorius Stedim Biotech's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €3.02
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of €3.02 mean?
Sartorius Stedim Biotech (CHIX:DIMP) has a Earnings per Share (Diluted) of €3.02 as of Jun. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Sartorius Stedim Biotech and its competitors. According to the industry distribution chart, Sartorius Stedim Biotech ranks #583 out of 657 companies in the Medical Devices & Instruments industry, placing it in the top 88.7%.
Is Sartorius Stedim Biotech's Earnings per Share (Diluted) too high?
Sartorius Stedim Biotech's current Earnings per Share (Diluted) is €3.02. Based on the distribution chart, Sartorius Stedim Biotech ranks #583 out of 657 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Sartorius Stedim Biotech has a GF Score™ of 84/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Sartorius Stedim Biotech's Earnings per Share (Diluted) compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sartorius Stedim Biotech ranks #583 out of 657 companies for Earnings per Share (Diluted). This places Sartorius Stedim Biotech in the lower half of its industry. The industry median Earnings per Share (Diluted) is 8.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Medical Devices & Instruments company?
The median Earnings per Share (Diluted) among Medical Devices & Instruments companies is 8.10, based on 657 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Sartorius Stedim Biotech and its competitors. For the Medical Devices & Instruments industry, the median Earnings per Share (Diluted) is 8.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sartorius Stedim Biotech's current Earnings per Share (Diluted) is €3.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius Stedim Biotech stock overvalued right now?
Based on GuruFocus' analysis, Sartorius Stedim Biotech (CHIX:DIMP) is currently considered Fairly Valued. The stock's GF Value™ is €201.50, compared to a current price of €182.45 — trading 9.5% below its estimated fair value. The current Earnings per Share (Diluted) is €3.02. Sartorius Stedim Biotech's overall GF Score™ is 84/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Sartorius Stedim Biotech (CHIX:DIMP), the current Earnings per Share (Diluted) is €3.02 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sartorius Stedim Biotech (CHIX:DIMP) Overvalued in 2026?
Based on GuruFocus' analysis, Sartorius Stedim Biotech stock appears to be undervalued.
The current stock price of €182.45 is trading 9.5% below its estimated GF Value™ of €201.50.
GuruFocus considers Sartorius Stedim Biotech to be Fairly Valued.
Key valuation signals for CHIX:DIMP:
Earnings per Share (Diluted): €3.02
GF Value™: €201.50 vs. price of €182.45 (9.5% below fair value)
No single metric tells the full story. See the CHIX:DIMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. It sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.
84GF Score
Get the complete analysis for CHIX:DIMP
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:DIMP has been successfully added to your 
